
San Diego-based Sirius Therapeutics innovates RNAi therapies for cardiovascular diseases.
Sirius Therapeutics, based in San Diego, California, is a pioneering biotechnology company dedicated to developing RNA interference (RNAi) therapies for cardiovascular diseases. The company's mission is to leverage RNAi technology to create innovative medical solutions that address significant cardiovascular risks globally. By focusing on novel RNAi therapies, Sirius aims to change the future of cardiovascular disease treatment and improve patient outcomes worldwide.
Sirius Therapeutics has made significant strides in advancing its RNAi therapies, including the recent milestone of dosing the first subject in a clinical trial in China. This achievement underscores the company's commitment to global healthcare innovation and its potential impact on cardiovascular disease management. Through its cutting-edge research and development efforts, Sirius Therapeutics is poised to make a substantial contribution to the field of biotechnology and patient care.

Sirnaomics
sirnaomics.com

Silence Therapeutics

Arcturus Therapeutics Holdings
arcturusrx.com

Traversa Therapeutics
traversathera.com

Orbital Therapeutics

Nextrna Therapeutics

VasoRx
vasrx.com

Switch Therapeutics
switchthera.com

Airna
airna.com

Rnaderm Therapeutics

Somagenics
somagenics.com

ReviR Therapeutics
revirtx.com

Sanegene Bio
sanegenebio.com

Alnylam Pharmaceuticals aln
alnylam.com

Solstice Biologics
Companies similar to Sirius Therapeutics include Sirnaomics, Silence Therapeutics, Arcturus Therapeutics Holdings and Traversa Therapeutics.
Sirius Therapeutics was founded in 2021.
Sirius Therapeutics' headquarters is located in San Diego, CA, US.
Sirius Therapeutics' most recent funding round was for $60M (USD) in October 2023.
As of Oct 9, 2023, Sirius Therapeutics has raised a total of $60M (USD).
Sirius Therapeutics has 5 employees as of Feb 4, 2024.